H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on BioXcel Therapeutics to $73 from $85 and keeps a Buy rating on the shares. The analyst reduced Igalmi revenue projections to reflect a more gradual sales ramp trajectory.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
- BioXcel Therapeutics announces first patient dosed in TRANQUILITY III study
- BioXcel Therapeutics price target raised to $24 from $18 at Mizuho
- Biotech Alert: Searches spiking for these stocks today